Qian Men-Bao, Huang Ji-Lei, Wang Li, Zhou Chang-Hai, Zhu Ting-Jun, Zhu Hui-Hui, He Yun-Ting, Zhou Xiao-Nong, Lai Ying-Si, Li Shi-Zhu
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Shanghai, China; NHC Key Laboratory of Parasite and Vector Biology, Shanghai, China; WHO Collaborating Center for Tropical Diseases, Shanghai, China; National Center for International Research on Tropical Diseases, Shanghai, China; School of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Shanghai, China; NHC Key Laboratory of Parasite and Vector Biology, Shanghai, China; WHO Collaborating Center for Tropical Diseases, Shanghai, China; National Center for International Research on Tropical Diseases, Shanghai, China.
J Infect. 2025 Jul;91(1):106528. doi: 10.1016/j.jinf.2025.106528. Epub 2025 Jun 3.
Clonorchiasis is highly endemic in China. The unavailability of fine-scale distribution of population with infection and at risk hinders the control.
This study established Bayesian geostatistical models to estimate age- and gender-specific prevalence of Clonorchis sinensis infection at high spatial resolution (5 × 5 km), based on the surveillance data in China between 2016 and 2021, together with socioeconomic, environmental and behavioral determinants. The population at risk and under infection, as well as chemotherapy need were then estimated.
In 2020, population-weighted prevalence of 0.67% (95% Bayesian credible interval (BCI): 0.58%-0.77%) was estimated for C. sinensis infection in China, corresponding to 9.46 million (95% BCI: 8.22 million-10.88 million) persons under infection. High prevalence was demonstrated in southern areas, including Guangxi (8.92%, 95% BCI: 7.10%-10.81%) and Guangdong (2.99%, 95% BCI: 2.43%-3.74%). A conservative estimation of 99.13 million (95% BCI: 88.61 million-114.40 million) people were at risk of infection, of which 51.69 million (95% BCI: 45.48 million-57.84 million) need chemotherapy.
Clonorchiasis is an important public health problem in China, especially in southern areas, due to the huge population at risk and large number of people under infection. Implementation of chemotherapy is urged to control the morbidity.
华支睾吸虫病在中国高度流行。缺乏感染人群和高危人群的精细分布情况阻碍了疾病防控工作。
本研究基于2016年至2021年中国的监测数据,结合社会经济、环境和行为决定因素,建立贝叶斯地理统计模型,以高空间分辨率(5×5千米)估计华支睾吸虫感染的年龄和性别特异性患病率。随后估算了高危人群、感染人群以及化疗需求。
2020年,中国华支睾吸虫感染的人群加权患病率估计为0.67%(95%贝叶斯可信区间(BCI):0.58% - 0.77%),这意味着有946万人(95% BCI:822万 - 1088万)受到感染。南方地区患病率较高,包括广西(8.92%,95% BCI:7.10% - 10.81%)和广东(2.99%,95% BCI:2.43% - 3.74%)。保守估计有9913万人(95% BCI:8861万 - 11440万)有感染风险,其中5169万人(95% BCI:4548万 - 5784万)需要化疗。
由于高危人群数量庞大且感染人数众多,华支睾吸虫病在中国是一个重要的公共卫生问题,尤其是在南方地区。迫切需要实施化疗以控制发病率。